Monday, November 27, 2006 7:00:00 AM PDT | VentureDeal Staff
GA -- Alimera Sciences announced the
receipt of the second and final tranche of its Series B financing. The
funding totaled $15.9 million and
brings Series B funding to-date to $31.8 million.
The company is developing ophthalmic pharmaceuticals and will use the funds to
further develop it's stage III trial drug Medidur TM which the
company claims treats diabetic macular edema.
All previous Series B investors participated in the tranche, including BA
Venture Partners, Intersouth Partners, Domain Associates, Venrock Partners and
Polaris Venture Partners.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
VentureDeal is a database that provides the latest information about venture capital firms, venture-backed technology companies and transactions throughout North America.
Learn More »
Email Sign Up
© 2014 VentureDeal, Inc., Menlo Park, CA. All Rights Reserved.